Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.32), $0.63 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $33.99 million versus the consensus estimate of $42.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.